Aalst Dermatology Clinic, Aalst, Belgium.
Clin Interv Aging. 2010 Apr 26;5:101-18. doi: 10.2147/cia.s9338.
Botulinum toxin type A treatment is the foundation of minimally invasive aesthetic facial procedures. Clinicians and their patients recognize the important role, both negative and positive, that facial expression, particularly the glabellar frown lines, plays in self-perception, emotional well-being, and perception by others. This article provides up-to-date information on fundamental properties and mechanisms of action of the major approved formulations of botulinum toxin type A, summarizes recent changes in naming conventions (nonproprietary names) mandated by the United States Food and Drug Administration, and describes the reasons for these changes. The request for these changes provides recognition that formulations of botulinum toxins (eg, onabotulinumtoxinA and abobotulinumtoxinA) are not interchangeable and that dosing recommendations cannot be based on any one single conversion ratio. The extensive safety, tolerability, and efficacy data are summarized in detail, including the patient-reported outcomes that contribute to overall patient satisfaction and probability treatment continuation. Based on this in-depth review, the authors conclude that botulinum toxin type A treatment remains a cornerstone of facial aesthetic treatments, and clinicians must realize that techniques and dosing from one formulation cannot be applied to others, that each patient should undergo a full aesthetic evaluation, and that products and procedures must be selected in the context of individual needs and goals.
A型肉毒毒素治疗是微创美容面部手术的基础。临床医生及其患者认识到面部表情（尤其是眉间皱眉线）在自我认知、情绪健康和他人感知方面的重要作用，既有积极的作用，也有消极的作用。本文提供了关于主要批准的 A 型肉毒毒素制剂的基本特性和作用机制的最新信息，总结了美国食品和药物管理局强制要求的最近在命名规范（非专利名称）方面的变化，并描述了这些变化的原因。对这些变化的要求表明，肉毒毒素制剂（例如，肉毒毒素 A 型和 abobotulinumtoxinA）不可互换，并且不能基于任何单一转换比来推荐剂量。详细总结了广泛的安全性、耐受性和疗效数据，包括有助于整体患者满意度和治疗持续概率的患者报告结果。基于这一深入审查，作者得出结论，A型肉毒毒素治疗仍然是面部美容治疗的基石，临床医生必须认识到，一种制剂的技术和剂量不能应用于其他制剂，每个患者都应进行全面的美学评估，并且必须根据个人需求和目标选择产品和程序。
